Sunridge International Corporate Update

Jan 19, 2010, 09:00 ET from Sunridge International

FOUNTAIN HILLS, Ariz., Jan. 19 /PRNewswire-FirstCall/ -- Sunridge International (OTC Bulletin Board: SNDZ) announces plans to expand its distributor marketing network through its wholly owned subsidiary Ophthalmic International.

Ophthalmic International has developed and patented Pneumatic Trabeculoplasty, "PNT", a two-minute, non-evasive, cost effective alternative treatment for Glaucoma and Ocular Hypertension.

The company has received its 2A approval for Europe.  This approval allows the company to market its product line, and recognizes PNT as an acceptable form of treatment for Glaucoma and Ocular Hypertension all throughout Europe.  This approval was the result of several years of successful clinical trials, and efforts performed by and on behalf of Ophthalmic International, at a cost of over 12 million dollars.  These clinical trials can be reviewed on our website, www.oi-pnt.com.

The company currently has a network of exclusive distributors in Europe.  "It is our intention to use the European approval to gain access to new markets in Asia, Africa and South America," says G. Richard Smith, CEO of Sunridge International.  "We have already been successful by securing marketing and treatment approval in Canada." Mr. Smith goes on to say, "that the companies' focus will also be on securing reimbursement approval for the procedure in the markets we are currently established in. We have been working closely with our distributors toward that goal and expect to soon be successful with our efforts."

Glaucoma is the second leading cause of blindness, effecting over 70 million people worldwide.  PNT has been proven (through studies completed over the last 10 yrs) to be a safe and effective treatment with no adverse side effects associated with it, unlike typical forms of glaucoma treatment.

Contact: Jeff Smith

Email: cdik837@aol.com

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that such  forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.

SOURCE Sunridge International



RELATED LINKS

http://www.oi-pnt.com/